Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag.

ABSTRACT:

Introduction

Parenteral prostanoids are the most potent therapies for pulmonary arterial hypertension (PAH) but are associated with complications and lifestyle limitations. Carefully selected stable patients may be considered for a transition from parenteral prostanoids to a more convenient oral regimen. We present our experience transitioning patients on parenteral prostanoids to selexipag on an outpatient basis.

Methods

This was a retrospective cohort study of all group 1 PAH patients on parenteral prostanoids who transitioned to selexipag using a standardized outpatient-based protocol. Hospitalization and routine prognostic data were recorded.

Results

Fourteen patients were followed for a median of 1,240 (1,052-1,528) days; all were functional class (FC) II (n</

SUBMITTER: Hinkamp C 

PROVIDER: S-EPMC9710435 | biostudies-literature | 2022 Sep-Dec

REPOSITORIES: biostudies-literature